Research & Literature

Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis.

Ungprasert P, Tanratana P, Srivali N

Thrombosis research 2015; (136(5)):1013-7.

Role of Complement in Autoimmune Hemolytic Anemia.

Berentsen S

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2015; (42(5)):303-10 doi:10.1159/000438964.

Hot therapy for cold agglutinin disease.

Jaeger U

Blood 2017; (130(4)):392-393 doi:10.1182/blood-2017-06-788463.

[Clinical features and prognosis of 17 patients with primary cold agglutinin disease].

Wu YY, Cao XX, Cai H, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017; (38(9)):789-793 doi:10.3760/cma.j.issn.0253-2727.2017.09.011.

Cold agglutinin disease complicating management of aortic dissection.

Bras J, Uminski K, Ponnampalam A

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(2)):236-238 doi:10.1016/j.transci.2018.02.024.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, et al.

Blood 2018; (132(5)):547-550 doi:10.1182/blood-2018-03-835413.

A Rare Non-Hemolytic Case of Idiopathic Cold Agglutinin Disease.

Erkus E, Kocak MZ, Aktas G, et al.

Clinical laboratory 2018; (64(6)):1075-1078 doi:10.7754/Clin.Lab.2018.180114.

Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease.

Berentsen S

Seminars in hematology 2018; (55(3)):141-149 doi:10.1053/j.seminhematol.2018.04.002.

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Röth A, Bommer M, Hüttmann A, et al.

Blood advances 2018; (2(19)):2543-2549 doi:10.1182/bloodadvances.2018024190.

Autoimmune hemolytic anemia.

Hill A, Hill QA

Hematology. American Society of Hematology. Education Program 2018; (2018(1)):382-389 doi:10.1182/asheducation-2018.1.382.

Cold agglutinins: fending off the attack.

Berentsen S

Blood 2019; (133(9)):885-886 doi:10.1182/blood-2019-01-894303.

Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.

Bylsma LC, Gulbech Ording A, Rosenthal A, et al.

Blood advances 2019; (3(20)):2980-2985 doi:10.1182/bloodadvances.2019000476.

Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.

Picod A, Provôt F, Coppo P

Presse medicale (Paris, France : 1983) 2019; (48(11 Pt 2)):319-327 doi:10.1016/j.lpm.2019.08.024.

Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.

Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al.

Journal of clinical pathology 2020; (73(9)):571-577 doi:10.1136/jclinpath-2019-206282.

Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18.

Małecka A, Delabie J, Østlie I, et al.

Blood advances 2020; (4(6)):993-996 doi:10.1182/bloodadvances.2020001608.

Cold agglutinin disease: where do we stand, and where are we going?

Berentsen S, Malecka A, Randen U, Tjønnfjord GE

Clinical advances in hematology & oncology : H&O 2020; (18(1)):35-44.

Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.

Broome CM, Cunningham JM, Mullins M, et al.

Research and practice in thrombosis and haemostasis 2020; (4(4)):628-635 doi:10.1002/rth2.12333.

Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.

Elba S, Castellino A, Soriasio R, et al.

Journal of medical case reports 2020; (14(1)):75 doi:10.1186/s13256-020-02380-2.

Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.

Morigi A, Casadei B, Argnani L, et al.

Leukemia & lymphoma 2021; (62(4)):1007-1009 doi:10.1080/10428194.2020.1855342.

Successful therapeutic plasma exchange in cold autoimmune hemolytic anemia in patient with disseminated tuberculosis.

Belfeki N, Strazzulla A, Isnard P, et al.

Reumatismo 2021; (72(4)):247-251 doi:10.4081/reumatismo.2020.1299.

Sutimlimab in Cold Agglutinin Disease.

Röth A, Barcellini W, D'Sa S, et al.

The New England journal of medicine 2021; (384(14)):1323-1334 doi:10.1056/NEJMoa2027760.

Cold agglutinin-induced hemolytic anemia during room temperature fluid resuscitation: a case report.

Kawai Y, Deguchi M, Mizouchi N, et al.

Journal of medical case reports 2021; (15(1)):169 doi:10.1186/s13256-021-02784-8.

Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.

Röth A, Fryzek J, Jiang X, et al.

Transfusion 2022; (62(1)):51-59 doi:10.1111/trf.16745.

Cold agglutinin syndrome secondary to splenic marginal zone lymphoma: a case report.

Portich JP, Blos B, Sekine L, Franz JPM

Hematology, transfusion and cell therapy 2023; (45(3)):403-405 doi:10.1016/j.htct.2021.07.009.

Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.

Gelbenegger G, Jaeger U, Fillitz M, et al.

British journal of haematology 2022; (198(4)):e59-e62 doi:10.1111/bjh.18289.

The Burden of Cold Agglutinin Disease on Patients' Daily Life: Web-Based Cross-sectional Survey of 50 American Patients.

Joly F, Schmitt LA, Watson PAM, et al.

JMIR formative research 2022; (6(7)):e34248 doi:10.2196/34248.

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?

Berentsen S, Barcellini W, D'Sa S, Jilma B

Immunotherapy 2022; (14(15)):1191-1204 doi:10.2217/imt-2022-0085.

Autoimmune hemolytic anemia associated with herpes zoster.

Baba Y, Kamata A, Kouno M, Takahashi S

The Journal of dermatology 2023; (50(3)):e94-e95 doi:10.1111/1346-8138.16594.

Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis.

García-Abellás P, Ferrer Gómez A, Bueno Sacristán D, et al.

EJHaem 2022; (3(4)):1181-1187 doi:10.1002/jha2.573.

Perioperative Management of a Patient With Severe Cold Agglutinin Disease Undergoing Total Hip Arthroplasty With a Cemented Stem: A Case Report.

Yamaguchi T, Hirate H, Kusano T, Inagaki Y

A&A practice 2022; (16(12)):e01647 doi:10.1213/XAA.0000000000001647.

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.

Garcia-Sanz R, Varettoni M, Jiménez C, et al.

Seminars in hematology 2023; (60(2)):90-96 doi:10.1053/j.seminhematol.2023.03.007.

Sutimlimab for the Treatment of Cold Agglutinin Disease.

Berentsen S

HemaSphere 2023; (7(5)):e879 doi:10.1097/HS9.0000000000000879.

Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.

Röth A, Barcellini W, D'Sa S, et al.

American journal of hematology 2023; (98(8)):1246-1253 doi:10.1002/ajh.26965.

The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms.

Berentsen S, Vos JMI, Malecka A, et al.

Expert review of hematology 2024; (17(8)):479-492 doi:10.1080/17474086.2024.2372333.

An Extensive Analysis and Comparison of Bone Marrow Aspiration and Bone Marrow Trephine Biopsy at a Tertiary Care Hospital in Jharkhand for Various Hematological and Non-hematological Illnesses.

Jawed MA, Paswan MK, Mahto SK, et al.

Cureus 2024; (16(6)):e62661 doi:10.7759/cureus.62661.

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

Röth A, Berentsen S, Barcellini W, et al.

EClinicalMedicine 2024; (74()):102733 doi:10.1016/j.eclinm.2024.102733.

[Cold agglutinin syndrome associated with infectious mononucleosis: A case report].

Garzón-Recalde DA, Rentería-Castillo E, Anda-Garay JC

Revista medica del Instituto Mexicano del Seguro Social 2024; (62(1)):1-7.

[The treatment strategies of autoimmune hemolytic anemia].

Yue WR, Wu T, Wang XQ

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(6)):615-620 doi:10.3760/cma.j.cn121090-20231027-00236.

Abdominal Aortic Aneurysm with Primary Cold Agglutinin Disease Treated with Endovascular Aortic Repair.

Tanaka S, Ohmine T, Imanaka R, Maeda T

Annals of vascular diseases 2025; (18(1)) doi:10.3400/avd.cr.24-00107.

Intervascular Large B-cell Lymphoma with Severe Anemia and a High-titer of Cold Agglutinin.

Oka T, Tsuji Y, Sakai T, et al.

Internal medicine (Tokyo, Japan) 2025; (64(22)):3279-3283 doi:10.2169/internalmedicine.5340-25.

A middle-aged woman with the initial symptom of acrocyanosis diagnosed with cold agglutinin disease: A case report.

Salimi B, Salimi M, Tavakoli Avval M, et al.

SAGE open medical case reports 2025; (13()):2050313X251342166 doi:10.1177/2050313X251342166.

Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016-2023.

Bozzi S, Umarje S, Hawaldar K, et al.

PloS one 2025; (20(6)):e0323843 doi:10.1371/journal.pone.0323843.

A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.

Sugimoto A, Yamada H, Tasaki K, et al.

International cancer conference journal 2025; (14(3)):235-240 doi:10.1007/s13691-025-00758-x.

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study (MyCOLD Study).

Chevalier K, Holub M, Palich R, et al.

American journal of hematology 2025; (100(9)):1557-1565 doi:10.1002/ajh.70010.

Cold Agglutinin Syndrome as the Initial Presentation of Acute Myeloid Leukemia: A Case Report.

Sadeghi MV, Vosough Z, Jahansouz D

Clinical case reports 2025; (13(10)):e71061 doi:10.1002/ccr3.71061.

Diagnosis and management of cold agglutinin disease.

Berentsen S

Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.